Jerusalem-based Enlivex reports promising results in treating small number of Covid-19 patients
Five patients in severe or critical condition make full recoveries in under 10 days after receiving drug as part of clinical trial
Shares of Enlivex were up 83% in Tel Aviv after resuming trade. They were halted in Tel Aviv and on Nasdaq pending the announcement.
All five had complete recoveries after an average of no more than 8.5 days following administration of Allocetra, while there were no reported severe adverse events.
It said that if approved, Allocetra "could potentially cover the gap that currently exists in treating severe or critical Covid-19 patients".
Enlivex said that based on the positive results of the five Covid-19 patients, along with good results of Allocetra in 10 sepsis patients in a previous study, it will shift recruitment of additional patients into a larger Phase II clinical trial of Covid-19 patients in severe or critical condition as soon as possible and subject to regulatory approval.
Any Covid-19 trials would run independently of Enlivex's planned Phase IIb clinical trial of Allocetra for the treatment of organ failures associated with sepsis expected to begin in the fourth quarter of 2020.
Founded in 2005, Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication.